San Diego, CA – According to filings with the U.S. Securities and Exchange Commission, Shoreline Biosciences is raising $43,000,002.00 in new funding. Sources indicate as part of senior management Chairman, Kleanthis Xanthopoulos played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Shoreline Biosciences

OUR VISION: To establish safe, effective, and affordable cell-based immunotherapies for the treatment of seriously ill patients. OUR MISSION: Through innovative thinking and tenacity we strive to discover and develop clinically effective immunotherapies using intelligently engineered iPSC-derived allogeneic cells to save lives. Shoreline’s proprietary cell therapy technology platform is based on deep expertise in iPSC differentiation methods and genetic programming of the IL-15/CISH pathway for enhanced metabolic fitness and persistence of the engineered NK Cells to improve anti-cancer activity.

To learn more about Shoreline Biosciences, visit http://www.shorelinebio.com/

Contact:
Kleanthis Xanthopoulos, Chairman
858-247-7033
https://www.linkedin.com/in/kleanthis-g-xanthopoulos-a4195210/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved